Immune and angiogenesis research
Thymosin Alpha-1 vs BPC-157: Research Comparison
Thymosin alpha-1 and BPC-157 are unrelated peptides studied in different fields. Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus, studied in immune signalling. BPC-157 is a synthetic 15-amino-acid peptide based on part of a gastric protein, studied mainly in rat models.
Side-by-side comparison
| Attribute | Thymosin Alpha-1 | BPC-157 |
|---|---|---|
| What it is | Natural 28-amino-acid thymic peptide | Synthetic 15-amino-acid peptide |
| Proposed mechanism | Signals through Toll-like receptors in dendritic cells (mouse and cell studies) | No single receptor established; linked to VEGFR2 and nitric-oxide signalling (cell and rat studies) |
| Human data | Randomised trials in chronic hepatitis B and sepsis with uncertain or no clear results | Three small uncontrolled pilot reports, about 30 people in total |
| Licensed status | Licensed as thymalfasin in more than 35 countries; not licensed in the UK or approved by the US FDA | Not a licensed medicine |
Detailed analysis
Thymosin alpha-1 was isolated from calf thymus and sequenced in 1977 (Goldstein et al., 1977). In mouse and cell studies it signalled through Toll-like receptors in dendritic cells, leading to their maturation (Romani et al., 2004). A synthetic version, thymalfasin, is licensed in more than 35 countries, mainly for chronic hepatitis B. The clinical evidence is mixed: a 2026 Cochrane review of 10 trials in chronic hepatitis B rated the evidence low or very low certainty, and a phase 3 trial in 1,106 adults with sepsis found no clear difference in 28-day deaths (Wu et al., 2025).
BPC-157 has no established receptor. In human blood-vessel lining cells and in rats it raised levels of VEGFR2 and switched on the Akt-eNOS pathway (Hsieh et al., 2017). Most studies come from one group in Zagreb and use rat or mouse injury models, and human data are limited to three small uncontrolled reports.
The two are not alternatives to each other: they are studied in different systems.
Key differences
- ·Thymosin alpha-1 is a natural thymic peptide; BPC-157 is a synthetic peptide based on a gastric protein.
- ·Thymosin alpha-1 is studied in immune signalling; BPC-157 is studied mainly in rat models of blood-vessel signalling.
- ·Thymosin alpha-1 has randomised human trials with mixed results; BPC-157 has only small uncontrolled reports.
- ·A synthetic form of thymosin alpha-1 is licensed in some countries; BPC-157 is not a licensed medicine.
Research summary
Thymosin alpha-1 has cell and mouse work (Romani et al., 2004) and randomised human trials with uncertain results (Wu et al., 2025). BPC-157 has mostly rat and mouse work (Hsieh et al., 2017). Supplied for laboratory research use only.